References: Hair growth and hair loss
Gan To Kagaku Ryoho. 1989 Jun;16(6):2263-7.
[Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer]
[Article in Japanese]
Irino S, Fujita J, Yamaji Y, Futami H, Hashimoto Y, Bungo M, Iuchi Y, Kamei M, Nakamura H, Hata Y, et al.
1st Dept. of Internal Medicine, Kagawa Medical School.
Twenty-three patients with small cell lung cancer (11 with limited disease and 12 with extensive disease) who had not received previous chemotherapy were treated with a combination of adriamycin (30 mg/m2, i.v., on day 1), cisplatin (80 mg/m2, i.v., on day 1) and etoposide (70 mg/m2, i.v., on day 1-5). This chemotherapy regimen was repeated at 3- or 4-week intervals for 3 to 5 treatment cycles. Among 22 evaluable patients, 5 showed complete response and 17 had a partial response (response rate 100%). The median response duration of 12 extensive disease patients was 21 months. There were 5 survivors for more than 2 years. Toxicity included moderate to severe hematologic toxicity, alopecia, nausea and vomiting. This combination chemotherapy appears to be optimal for the treatment of small cell lung cancer.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2544150&dopt=Abstract
Gan To Kagaku Ryoho. 1985 Oct;12(10):2011-7.
[A phase II study of NK171 (etoposide)]
[Article in Japanese]
Kimura K, Niitani H.
A phase II study of NK171 (etoposide), a semisynthetic derivative of podophyllotoxin, was carried out in patients with primary lung cancer at 46 institutes throughout Japan. Out of 198 patients registered for the study, 130 were judged eligible by the committee for extramural review and the response rate was 13.8% (18/130). The response rates were 17.4% (15/86) by i.v. administration and 6.8% (3/44) by oral administration. In the case of i.v. administration, the response was observed only for small cell carcinoma and the response rate was 32.6% (15/46). In the case of oral administration, the response rates were 16.7% (1/6) for squamous cell carcinoma, 12.5% (1/8) for adenocarcinoma and 3.4% (1/29) for small carcinoma. As a hematological toxicity, leukopenia (less than 3,000/mm3) was observed in 66.7% and 35.3% of cases treated, for i.v. and oral administration, respectively. With regard to the clinical picture, alopecia was observed at high incidences of 73-82% in the cases of both i.v. and oral administration.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2996442&dopt=Abstract
Acta Derm Venereol. 1992 Sep;72(5):373-5.
The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate.
van der Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H.
Department of Dermatology, University of Nijmegen, The Netherlands.
Substantial evidence indicates that genetic factors may have a role in the etiology of alopecia areata (AA). Most studies, however, provide only general information on the familial incidence but fail to specify family relationships. We therefore obtained information on the incidence of AA in first degree relatives of 348 severely affected patients. In 7% one of the parents was affected. Among the siblings of the patients 3% had developed AA, while AA was present in 2% of the children. Taking into account the age of the children, their lifetime risk was calculated to approach 6%. However, a severe type of AA is to be expected only in about 2% of the children. The degree of involvement observed in the patients did not influence the frequency and type of AA present in their first degree relatives.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1361288&dopt=Abstract
Lipitor
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Hair loss research references ||
E-Mail Us